A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study of COR388 HCl in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2018
Price : $35 *
At a glance
- Drugs COR-388 (Primary)
- Indications Alzheimer's disease; Neurodegenerative disorders
- Focus First in man; Pharmacokinetics
- Sponsors Cortexyme
- 17 Apr 2018 Status changed from recruiting to completed.
- 06 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Mar 2018.
- 04 Jan 2018 According to a Cortexyme media release, the first cohort has been dosed in this trial.